Cephalalgia : an international journal of headache最新文献

{"title":"Are the ICHD-3 criteria for headache attributed to idiopathic intracranial hypertension valid? Headache phenotyping and field-testing in newly diagnosed idiopathic intracranial hypertension.","authors":"N. S. Hansen, J. J. Korsbæk, H. Yri, R. Jensen, Dagmar Beier","doi":"10.1177/03331024241248210","DOIUrl":"https://doi.org/10.1177/03331024241248210","url":null,"abstract":"BACKGROUND\u0000Headache burden is substantial in idiopathic intracranial hypertension. The classification of idiopathic intracranial hypertension headache by the International Classification of Headache Disorders (ICHD) is an important tool for research and clinical purposes.\u0000\u0000\u0000METHODS\u0000We phenotyped headaches and tested sensitivity and specificity of the ICHD-3 criteria for idiopathic intracranial hypertension headache in a prospective cohort of patients suspected of idiopathic intracranial hypertension at two tertiary headache centers.\u0000\u0000\u0000RESULTS\u0000Sensitivity was 93% and specificity was 100% of ICHD-3 criteria for idiopathic intracranial hypertension-related headache validated in idiopathic intracranial hypertension (n = 140) and patients in whom idiopathic intracranial hypertension was suspected but disproven (n = 103). The phenotype of new/worsened headaches related to idiopathic intracranial hypertension suspicion was equally migraine-like (p = 0.76) and tension-type-like (p = 0.08). Lumbar puncture opening pressure was higher (p < 0.0001) and pulsatile tinnitus more frequent (p < 0.0001) in idiopathic intracranial hypertension patients, but neither improved the applicability of the headache criteria, nor did papilledema.\u0000\u0000\u0000CONCLUSION\u0000Headache phenotype is not distinct in idiopathic intracranial hypertension. ICHD-3 criteria for idiopathic intracranial hypertension headache are sensitive and specific, but simplicity can be improved without compromising accuracy. We propose that a new or worsened headache temporally related to active idiopathic intracranial hypertension is a sufficient criterion for idiopathic intracranial hypertension headache regardless of headache phenotype or accompanying symptoms, and that elements of idiopathic intracranial hypertension diagnostics (papilledema and opening pressure) be segregated from headache criteria.Trial Registration: ClinicalTrials.gov Identifier: NCT04032379.","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":"215 ","pages":"3331024241248210"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine.","authors":"David J Whitaker, Gina M. Dumkrieger, Joseph G Hentz, D. Dodick, T. Schwedt","doi":"10.1177/03331024241249747","DOIUrl":"https://doi.org/10.1177/03331024241249747","url":null,"abstract":"OBJECTIVE\u0000While a substantial body of research describes the disabling impacts of migraine attacks, less research has described the impacts of migraine on physical functioning between migraine attacks. The objective of this study is to describe physical impairment during and between migraine attacks as a dimension of burden experienced by people living with chronic migraine.\u0000\u0000\u0000METHODS\u0000The physical impairment domain of the Migraine Physical Function Impact Diary was recorded in headache diaries from the Medication Overuse Treatment Strategy trial. Days with moderate to severe headache were used to approximate migraine attacks. Factor analysis and regression analysis were used to describe associations between migraine and physical impairment.\u0000\u0000\u0000RESULTS\u000077,662 headache diary entries from 720 participants were analyzed, including 25,414 days with moderate to severe headache, 19,149 days with mild headache, and 33,099 days with no headache. Mean physical impairment score was 41.5 (SD = 26.1) on days with moderate to severe headache, 12.8 (SD = 15.0) on days with mild headache, and 5.2 (SD = 13.1) on days with no headache. Physical impairment on days with mild headache and days with no headache was significantly associated with days since last moderate to severe headache, physical impairment with last moderate to severe headache, mild headache (compared to no headache), depression, hypersensitivities and cranial autonomic symptoms.\u0000\u0000\u0000CONCLUSIONS\u0000Physical impairment occurs on migraine and non-migraine days. Study participants with frequent headaches, symptoms of depression, hypersensitivities and cranial autonomic symptoms experience physical impairment at a higher rate on days with no headache and days with mild headache.Clinical Trial Registration: ClinicalTrials.gov (NCT02764320).","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":"340 ","pages":"3331024241249747"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.","authors":"R. Croop, Gary Berman, D. Kudrow, Kathleen Mullin, A. Thiry, Meghan Lovegren, G. L’Italien, Richard B Lipton","doi":"10.1177/03331024241232944","DOIUrl":"https://doi.org/10.1177/03331024241232944","url":null,"abstract":"BACKGROUND\u0000The present study evaluated the long-term safety and tolerability of rimegepant, an orally administered small molecule calcitonin gene-related peptide receptor antagonist, in people with migraine.\u0000\u0000\u0000METHODS\u0000This multicenter, long-term, open-label safety study included adults (≥18 years) with ≥1 year history of migraine who were sequentially enrolled into three groups: participants in the first two groups had either 2-8 or 9-14 moderate to severe migraine attacks per month by history and treated as needed (pro re nata [PRN]) with one rimegepant 75 mg oral tablet up to once per calendar day for 52 weeks (PRN 2-8 and PRN 9-14); a third group, included to collect safety data during higher-frequency dosing, had 4-14 moderate to severe migraine attacks per month by history and who took one rimegepant tablet every other day as scheduled dosing plus PRN dosing of one rimegepant tablet for migraine attacks of any severity on nonscheduled dosing days for 12 weeks (every other day (EOD) + PRN).\u0000\u0000\u0000RESULTS\u0000Overall, 1800 participants self-administered rimegepant (PRN 2-8: n = 1033; PRN 9-14: n = 481; EOD + PRN: n = 286). The most common on-treatment adverse events (AEs) were upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. Serious AEs considered possibly (n = 1) or unlikely (n = 9) related to rimegepant were reported in ten (0.6%) participants. No signal of drug-induced liver injury because of rimegepant was identified.\u0000\u0000\u0000CONCLUSIONS\u0000Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks or PRN for up to 52 weeks was safe and well tolerated. No signal of hepatotoxicity, potential drug abuse, or medication-overuse headache was identified.Trial registration: Clinicaltrials.gov: NCT03266588.","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":"41 12","pages":"3331024241232944"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.","authors":"David García-Azorín, Cristina Martínez-Badillo, J. Camiña Muñiz, A. Gago-Veiga, Noemi Morollón Sánchez, V. González-Quintanilla, J. Porta-Etessam, Álvaro Sierra-Mencía, N. González-García, Yesica González-Osorio, Marcos Polanco-Fernandez, Andrea Recio-García, Robert Belvís Nieto, Á. Guerrero-Peral","doi":"10.1177/03331024241248833","DOIUrl":"https://doi.org/10.1177/03331024241248833","url":null,"abstract":"INTRODUCTION\u0000Effectiveness of candesartan in migraine prevention is supported by two randomized controlled trials. We aimed to assess the effectiveness, tolerability, and response predictors of candesartan in the preventive treatment of migraine.\u0000\u0000\u0000METHODS\u0000Observational, multicenter, prospective cohort study. The 50%, 75% and 30% responder rates, between weeks 8-12 and 20-24, were compared with the baseline. Treatment emergent adverse effects were systematically evaluated. Response predictors were estimated by multivariate regression models.\u0000\u0000\u0000RESULTS\u0000Eighty-six patients were included, 79.1% females, aged 39.5 (inter-quartile range [IQR] 26.3-50.3), with chronic migraine (43.0%), medication overuse headache (55.8%) and a median of two (inter-quartile range: 0.75-3) prior preventive treatments. At baseline patients had 14 (10-24) headache and 8 (5-11) migraine days per month. The 30%, 50% and 75% responder rates were 40%, 34.9% and 15.1% between weeks 8-12, and 48.8%, 36%, and 18.6% between weeks 20-24. Adverse effects were reported by 30 (34.9%) and 13 (15.1%) patients between weeks 0-12 and 12-24, leading to discontinuation in 15 (17.4%) patients. Chronic migraine, depression, headache days per month, medication overuse headache, and daily headache at baseline predicted the response between weeks 20-24.\u0000\u0000\u0000CONCLUSION\u0000Candesartan effectiveness and tolerability in migraine prevention was in line with the clinical trials' efficacy.Trial registration: The study protocol is registered in ClinicalTrials.gov (NCT04138316).","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":"68 4","pages":"3331024241248833"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Headache at the chronic stage of cerebral venous thrombosis.","authors":"Alexandre Souza Bossoni,&nbsp;Mario Fernando Prieto Peres,&nbsp;Claudia da Costa Leite,&nbsp;Ida Fortini,&nbsp;Adriana Bastos Conforto","doi":"10.1177/03331024221113825","DOIUrl":"https://doi.org/10.1177/03331024221113825","url":null,"abstract":"<p><strong>Background: </strong>Headache is the most frequent symptom of cerebral venous thrombosis (CVT) but there is limited information about the frequency and phenotype of headache, weeks to months after cerebral venous thrombosis (post-cerebral venous thrombosis headache, PCH).</p><p><strong>Objective: </strong>To assess the frequency, characteristics and predictors of PCH.</p><p><strong>Methods: </strong>In this cross-sectional study, the frequency and characteristics of PCH were assessed in cerebral venous thrombosis survivors. Patients were interviewed between six months and five years after the cerebral venous thrombosis diagnosis. Clinical and imaging characteristics at the time of cerebral venous thrombosis diagnosis, as well as history of headache prior to cerebral venous thrombosis were compared in subjects with (Group_PCH) and without PCH (Group_control).</p><p><strong>Results: </strong>Subjects (n = 100; 82% women) were assessed, on average, at 1.1 ± 1.6 years of follow-up. PCH was present in 59% of the patients, phenotypes of tension-type-like headache were present in 31/59 (52.6%) and of migraine-like headache in 16/59 (27.1%). History of primary headache prior to cerebral venous thrombosis was significantly more common (OR: 6.4; 95% CI: 1.7-36.3) in Group_PCH (33.9%) than in Group_control (7.3%).</p><p><strong>Conclusion: </strong>PCH was present in more than half of the patients. History of prior headache may be a risk factor for PCH. Prospective studies are required to confirm these findings and determine mechanisms, as well as interventions for prevention and treatment of PCH.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1476-1486"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of cytokines in migraine: A systematic review.","authors":"Janu Thuraiaiyah,&nbsp;Mai Erritzøe-Jervild,&nbsp;Haidar Muhsen Al-Khazali,&nbsp;Henrik Winther Schytz,&nbsp;Samaira Younis","doi":"10.1177/03331024221118924","DOIUrl":"https://doi.org/10.1177/03331024221118924","url":null,"abstract":"<p><strong>Background: </strong>Cytokines are important endogenous substances that are involved in immune and inflammatory responses. Neurogenic inflammation has been proposed to play a role in migraine involving altered cytokine levels. Therefore, we aimed to provide a systematic review on the current knowledge on cytokine levels in migraine patients during and outside attacks.</p><p><strong>Methods: </strong>Databases of PubMed and Embase were systematically searched for studies investigating cytokine levels in migraine patients during and outside attacks.</p><p><strong>Results: </strong>Screening yielded identification of 45 articles investigating 18 cytokines in total. We found that the interictal level of the anti-inflammatory cytokine, interleukin 10, was decreased, while the level of transforming growth factor beta 1 was increased in migraine patients compared to controls. Levels of pro-inflammatory cytokines, tumor necrosis factor α and interleukin 6, were increased outside attacks compared to controls. Ictal levels of cytokines were unchanged or varying compared to the interictal state in migraine patients. Three studies reported dynamic cytokines levels during the course of an attack.</p><p><strong>Conclusion: </strong>The findings of the current review underline a possible involvement of cytokines in the proposed inflammatory mechanisms of migraine. However, future studies are needed to expand our knowledge of the exact role of cytokines in the migraine pathophysiology with focus on cytokines TNF-α, IL-1ß, IL-6 and IL-10 while applying refined methodology.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1565-1588"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40694449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura.","authors":"Yu-Chien Tsao,&nbsp;Yen-Feng Wang,&nbsp;Jong-Ling Fuh,&nbsp;Wei-Ta Chen,&nbsp;Kuan-Lin Lai,&nbsp;Hung-Yu Liu,&nbsp;Shuu-Jiun Wang,&nbsp;Shih-Pin Chen","doi":"10.1177/03331024221123074","DOIUrl":"https://doi.org/10.1177/03331024221123074","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the clinical correlates of visual symptoms in patients with migraine.</p><p><strong>Method: </strong>Patients with migraine that attended our headache clinics were enrolled. Headache profiles, disability, and comorbidities were acquired with structured questionnaires. A semi-structured visual phenomenon questionnaire was also used to assess the characteristics of visual symptoms, including visual aura in patients with migraine with aura and transient visual disturbance in patients with migraine without aura. Headache specialists interviewed with the participants for the ascertainment of diagnosis and verification of the questionnaires.</p><p><strong>Result: </strong>Migraine with aura patients with visual aura (n = 743, female/male = 2.3, mean age: 34.7 ± 12.2 years) and migraine without aura patients with non-aura transient visual disturbance (n = 1,808, female/male = 4.4, mean age: 39.4 ± 12.6 years) were enrolled. Patients with transient visual disturbance had higher headache-related disability and more psychiatric comorbidities. Chronic migraine was more common in migraine without aura than migraine with aura patients (41.9% vs. 11.8%, OR = 5.48 [95% CI: 4.33-7.02], <i>p</i> < 0.001). The associations remained after adjusting confounding factors.</p><p><strong>Conclusion: </strong>Presence of non-aura transient visual disturbance may suggest a higher migraine-related disability and is linked to higher risk of chronic migraine than typical migraine aura in migraine patients. Further studies are needed to elucidate the potential mechanism.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1487-1497"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40354817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitivity of the SNNOOP10 list in the high-risk secondary headache detection.","authors":"David García-Azorín,&nbsp;Jaime Abelaira-Freire,&nbsp;Nuria González-García,&nbsp;Esther Rodriguez-Adrada,&nbsp;Henrik Winther Schytz,&nbsp;Mads Barloese,&nbsp;Ángel Luis Guerrero,&nbsp;Jesús Porta-Etessam,&nbsp;Francisco Javier Martín-Sánchez","doi":"10.1177/03331024221120249","DOIUrl":"https://doi.org/10.1177/03331024221120249","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the diagnostic accuracy of the SNNOOP10 list in the detection of high-risk headaches.</p><p><strong>Methods: </strong>Patients that visited the Hospital Clínico San Carlos (Madrid) emergency department due to headache that were allocated to a Manchester Triage System level between critical and urgent were prospectively included but retrospectively analysed. A researcher blind to the patients' diagnosis administered a standardised questionnaire and afterwards a neurologist blind to the questionnaire results diagnosed the patient according to the International Classification of Headache Disorders. The primary endpoint was to assess the sensitivity of the SNNOOP10 list in the detection of high-risk headaches. Secondary endpoints included the evaluation of the sensitivity, specificity, positive predictive value, negative predictive value and area under the curve of each SNNOOP10 item.</p><p><strong>Results: </strong>Between April 2015 and October 2021, 100 patients were included. Patients were 44 years old (inter-quartile range: 33.6-64.7) and 57% were female. We identified 37 different diagnoses. Final diagnosis was a primary headache in 33%, secondary headache in 65% and cranial neuralgia in 2%. There were 46 patients that were considered as having high-risk headache. Patients from the primary headache group were younger and more frequently female. Sensitivity of SNNOOP10 list was 100% (95% confidence interval: 90.2%-100%). The items with higher sensitivity were neurologic deficit or disfunction (75.5%), pattern change or recent onset of the headache (64.4%), onset after 50 years (64.4%). The most specific items were posttraumatic onset of headache (94.5%), neoplasm in history (89.1%) and systemic symptoms (89%). The area under the curve of the SNNOOP10 list was 0.66 (95% CI: 0.55-0.76).</p><p><strong>Conclusion: </strong>The red flags from the SNNOOP10 list showed a 100% sensitivity in the detection of high-risk headache disorders.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1521-1531"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40439505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey.","authors":"Irene de Boer,&nbsp;Anna Ambrosini,&nbsp;Rashmi B Halker Singh,&nbsp;Betül Baykan,&nbsp;Dawn C Buse,&nbsp;Cristina Tassoreli,&nbsp;Rigmor H Jensen,&nbsp;Patricia Pozo-Rosich,&nbsp;Gisela M Terwindt","doi":"10.1177/03331024221123081","DOIUrl":"https://doi.org/10.1177/03331024221123081","url":null,"abstract":"<p><strong>Background: </strong>It is well recognized that underrepresented and minoritized groups do not have the same career opportunities. However, there are limited data on the range and specifics of potential barriers that withhold people in headache medicine and science from reaching their full potential. Moreover, people from different geographical regions often perceive different challenges. We aimed to identify world-wide perceived career barriers and possibilities for promoting equality amongst professionals in the headache fields.</p><p><strong>Methods: </strong>A cross-sectional online survey was conducted among professionals in the field of headache globally. The questions of the survey were aimed at assessing perceived career barriers in four domains: professional recognition, opportunities in scientific societies, clinical practice, and salary and compensation. Perceived mentorship was also assessed.</p><p><strong>Results: </strong>In total 580 responders completed the survey (55.3% women). Gender was the most important perceived barrier in almost all domains. Additionally, country of birth emerged as an important barrier to participation in international scientific societies. Career barriers varied across world regions.</p><p><strong>Conclusion: </strong>It is essential that longstanding and ongoing disparities by gender and country of origin for professionals in the headache field are globally acknowledged and addressed in areas of recruitment, retention, opportunities, mentor- and sponsorships, and advancement.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1498-1509"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/d0/10.1177_03331024221123081.PMC9693724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33447778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache.","authors":"Jean Schoenen,&nbsp;Agneta Henriette Snoer,&nbsp;Roemer B Brandt,&nbsp;Rolf Fronczek,&nbsp;Diana Y Wei,&nbsp;Chin-Sang Chung,&nbsp;Hans-Christoph Diener,&nbsp;David W Dodick,&nbsp;Denys Fontaine,&nbsp;Peter J Goadsby,&nbsp;Manjit Singh Matharu,&nbsp;Arne May,&nbsp;James S McGinley,&nbsp;Stewart J Tepper,&nbsp;Rigmor Højland Jensen,&nbsp;Michel D Ferrari","doi":"10.1177/03331024221120266","DOIUrl":"https://doi.org/10.1177/03331024221120266","url":null,"abstract":"<p><p>In 1995, a committee of the International Headache Society developed and published the first edition of the <i>Guidelines for Controlled Trials of Drugs in Cluster Headache.</i> These have not been revised. With the emergence of new medications, neuromodulation devices and trial designs, an updated version of the International Headache Society <i>Guidelines for Controlled Clinical Trials in Cluster Headache</i> is warranted. Given the scarcity of evidence-based data for cluster headache therapies, the update is largely consensus-based, but takes into account lessons learned from recent trials and demands by patients. It is intended to apply to both drug and neuromodulation treatments, with specific proposals for the latter when needed. The primary objective is to propose a template for designing high quality, state-of-the-art, controlled clinical trials of acute and preventive treatments in episodic and chronic cluster headache. The recommendations should not be regarded as dogma and alternative solutions to particular methodological problems should be explored in the future and scientifically validated.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1450-1466"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40672696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}